SLSi Won Lee

Si Won Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Si Won Lee has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Beodeul Kang

    Division of Medical Oncology, CHA Bundang Medical Center, Seongnam, Republic of Korea

    3 shared publications
  • Minkyu Jung

    Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

    3 shared publications
  • Choong-Kun Lee

    Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

    2 shared publications
  • Eun Hee Jung

    Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

    2 shared publications
  • Hye Jin Choi

    Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

    2 shared publications
  • Jee Hyun Kim

    Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

    2 shared publications

Latest Publications

  • Open Access

    Impact of Junior Physicians’ Resignation on Palliative Sedation Practices: A Retrospective Single-Center Study in South Korea

    by Moonki Hong, Si Won Lee, Minkyu Jung

    Moonki Hong, M.D., Si Won Lee, M.D. and Minkyu Jung, M.D., Ph.D.. J Hosp Palliat Care 2026;29:21-5. https://doi.org/10.14475/jhpc.2026.29.1.21

  • Optimizing Intravenous Patient-Controlled Analgesia for Cancer Pain: A Randomized Controlled Trial on Adjusted Background Infusion Rates

    by Min Jung Geum, Si Won Lee, Choong-Kun Lee, Minkyu Jung, Do-Hyeong Kim, Young Chul Yoo, Hye Jin Choi

    PURPOSE: Patient-controlled analgesia (PCA) has been considered for managing cancer pain; however, limited research has been conducted on optimizing continuous infusion rates with PCA. This study aimed to evaluate the efficacy and safety of a method that optimizes background infusion (BI) alongside PCA for titrating intravenous (IV) morphine in managing cancer-related pain. METHODS: Forty-four patients with solid tumors who could not manage pain with oral or transdermal opioid analgesics were randomly assigned in a 1:1 ratio to receive IV morphine through PCA or the conventional method. In the PCA group, the BI rate was automatically adjusted on the basis of the frequency and interval of bolus button presses; contrastingly, BI rate in the conventional group was adjusted at the discretion of the medical staff. The primary outcome was the daily number of patient complaints of breakthrough pain (numeric rating scale ≥4). RESULTS: The PCA group reported a significant decrease in breakthrough pain complaints at 24 hours (median, 0 v 3 times/d; P = .012) and a lower proportion of nonresponders at 24 hours (21% v 55%; P = .048) compared with the conventional group. The total daily IV dose of morphine increased in the PCA group and exhibited a significant difference between two groups within 48 hours (median, 76.80 v 44.42 mg/d; P = .036). No uncontrolled opioid-related adverse effects were observed in either group. CONCLUSION: PCA, with an optimized BI rate, facilitated faster titration of IV morphine than the conventional method, achieving tolerable and rapid pain relief.


  • Open Access

    Development of a Prediction Model for Delirium in Hospitalized Patients with Advanced Cancer

    by Eun Hee Jung, Shin Hye Yoo, Si Won Lee, Beodeul Kang, Yu Jung Kim

    Purpose Delirium is a common neurocognitive disorder in patients with advanced cancer and is associated with poor clinical outcomes. As a potentially reversible phenomenon, early recognition of delirium by identifying the risk factors demands attention. We aimed to develop a model to predict the occurrence of delirium in hospitalized patients with advanced cancer.Materials and Methods This retrospective study included patients with advanced cancer admitted to the oncology ward of four tertiary cancer centers in Korea for supportive cares and excluded those discharged due to death. The primary endpoint was occurrence of delirium. Sociodemographic characteristics, clinical characteristics, laboratory findings, and concomitant medication were investigated for associating variables. The predictive model developed using multivariate logistic regression was internally validated by bootstrapping.Results From January 2019 to December 2020, 2,152 patients were enrolled. The median age of patients was 64 years, and 58.4% were male. A total of 127 patients (5.9%) developed delirium during hospitalization. In multivariate logistic regression, age, body mass index, hearing impairment, previous delirium history, length of hospitalization, chemotherapy during hospitalization, blood urea nitrogen and calcium levels, and concomitant antidepressant use were significantly associated with the occurrence of delirium. The predictive model combining all four categorized variables showed the best performance among the developed models (area under the curve 0.831, sensitivity 80.3%, and specificity 72.0%). The calibration plot showed optimal agreement between predicted and actual probabilities through internal validation of the final model.Conclusion We proposed a successful predictive model for the risk of delirium in hospitalized patients with advanced cancer.


  • Comparison between two methods of intravenous titration of morphine: Optimizing BI mode of patient-controlled analgesia versus conventional method.

    by Min Jung Geum, Si Won Lee, Choong-Kun Lee, Minkyu Jung, Do Hyeong Kim, Young Chul Yoo, Hye Jin Choi

    204 Background: The titration of opioids to the optimal dose without side effects is an important and essential gateway in cancer pain management. However, sufficient pain control may not be achievable until the titration is complete because the change in the dose of opioids is calculated based on the opioid demand over the previous 24 hours. A recent patient-controlled analgesia (PCA) device could perform in an optimizing B.I. mode in which the background infusion rate was adjustable in accordance with the patient’s use of a bolus button. Therefore, we aimed to compare the efficacy and safety of the conventional method and the optimizing B.I. method of PCA in the titration of intravenous morphine in patients with cancer pain. Methods: This was a prospective, randomized, open-label, active-controlled study. After randomization, the previously administered opioids were switched to intravenous morphine and dose titration was initiated. In the conventional group, the dosage of continuous infusion morphine over the next day was adjusted based on the total amount of morphine administered during the previous 24 hours. In the PCA group, morphine titration was performed by increasing or decreasing the background infusion rate immediately in accordance with the frequency and interval of pressing the bolus button. The patients received pain management in this manner for at least three days and we compared the two groups by collecting their pain-related outcomes via medical records and questionnaires. Results: A total of 39 patients were enrolled, of whom 20 were assigned to the conventional group and 19 to the PCA group. The number of breakthrough pain complaints (NRS ≥ 4) by patients to the medical staff decreased in the PCA group, showing a difference from the conventional group within 24 hours (p = 0.012). The total daily dose of morphine was increased significantly at 0–24 hours in the PCA group (p < 0.001) and then slightly increased until 72 hours. The patient-reported pain reduction rate increased at 24–48 hours (p = 0.022) and was maintained until 72 hours in the PCA group. There was no statistically significant change in the conventional group during the study period for the above items. The conversion rate to oral or transdermal opioids after 72 hours was higher in the PCA group (p = 0.010). There were no uncontrolled side effects due to morphine titration in either group. Conclusions: Patients using the PCA with optimizing B.I. mode showed faster intravenous morphine titration and higher morphine consumption than the conventional method and achieved tolerable and rapid pain relief. This study revealed that early active opioid titration is necessary for patients admitted for pain control. It also suggested that the patient's actual opioid demands for pain control may be greater than the amount of opioid used through conventional titration methods. Clinical trial information: KCT0004008.

  • Clinical Outcomes of Operating an Acute Palliative Care Unit at a Comprehensive Cancer Center

    by Eun Hee Jung, Si Won Lee, Yu Jung Kim, Beodeul Kang, Koung Jin Suh, Ju Hyun Lee, Esther Jeon, Dahee Kim, Sung Soun Hur, Ji Yun Lee, et al.

    PURPOSE: Acute palliative care units (APCUs) are inpatient services in tertiary hospitals that provide intensive symptom management and assist in hospital discharge for transitions to hospice care. We aimed to analyze the clinical outcomes of operating an APCU at a comprehensive cancer center. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 1,440 consecutive patients admitted to the APCU and analyzed demographic and clinical information, discharge outcomes, symptom assessments using the Edmonton Symptom Assessment System, spiritual distress, and financial distress. RESULTS: The median age of patients was 67.0 (range, 23-97) years, and 41% were female. The most common primary cancer types were lung (21.9%), hepatopancreatobiliary (14.1%), and colorectal cancers (12.9%). The median length of stay was 8.0 days (range, 1-60 days), and 31.0% of patients died in the APCU. Death in the APCU showed a significant decrease over time, and overall inpatient death in oncology wards did not increase after APCU opening. In total, 44.7% of patients were discharged to government-certified hospice centers. The proportion of patients discharged to certified hospice centers increased from 32.2% in 2015 to 62.4% in 2018. Among 715 patients with a follow-up evaluation 1 week after admission, Edmonton Symptom Assessment System symptom scores, spiritual distress, and financial distress showed statistically significant improvements compared with the baseline symptom scores ( P < .001). This improvement was limited to patients who did not die in the APCU. CONCLUSION: Patients with advanced cancer admitted to the APCU may experience significant improvements in distressing symptoms. The majority of patients requiring transition to hospice were successfully transferred to certified hospice centers. The percentage discharged alive improved over time.


  • Mid-upper Arm Circumference as an Indicator of Quality of Life of Patients with Advanced Cancer

    by Seon-Hye Won, Yusuke Hiratsuka, Sang-Yeon Suh, Hayoung Bae, Sung-Eun Choi, Yu Jung Kim, Beodeul Kang, Si Won Lee, Koung Jin Suh, Se Hyun Kim, et al.

    Objective: Mid-upper arm circumference (MUAC) has been used to assess malnutrition and health status across various disease groups. However, it is unclear whether MUAC is associated with quality of life (QOL) of patients with advanced cancer. Our goal was to investigate the relationship between MUAC and QOL in ambulatory out-patients with advanced cancer. Method: This was a cross-sectional study conducted in a tertiary cancer center in South Korea. A total of 200 patients with advanced cancer at oncology clinics of Seoul National University Bundang Hospital from March 2016 to January 2019 were enrolled. Out-patients with advanced cancer whose survival was expected to be less than one year by their oncologists were enrolled. QOL of patients was evaluated using the European Organization for Research and Treatment of Cancer quality of life questionnaire core 30 (EORTC QLQ-C30). Associations of QOL with MUAC and nutritional parameters were examined with generalized linear models. Results: The most common cancer sites were the lung, colon or rectum, and genitourinary tract. In univariate analyses, significant factors associated with higher summary score of EORTC QLQ-C30 were higher MUAC (≥ 26.5 cm, p < 0.001), higher body mass index (BMI) (≥ 22 kg/m2, p < 0.001), higher serum albumin (≥ 3.7 g/dL, p < 0.01), higher creatinine (≥ 0.8 mg/dL, p = 0.023), and higher uric acid (≥ 5 mg/dL, p < 0.01). In multivariate analysis, higher serum albumin (≥ 3.7 g/dL, p < 0.01) and higher MUAC (≥ 26.5 cm, p = 0.03) were independently associated with better summary score of EORTC QLQ-C-30. Conclusion: MUAC was highly associated with QOL in terms of summary score and overall health status. Thus, MUAC, with its simplicity, can be a useful tool to reflect QOL in patients with advanced cancer.


  • Open Access

    Performance of clinician prediction of survival in oncology outpatients with advanced cancer

    by Yu Jung Kim, Seok Joon Yoon, Sang-Yeon Suh, Yusuke Hiratsuka, Beodeul Kang, Si Won Lee, Hong-Yup Ahn, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, et al.

    Background: We aimed to investigate the performance of clinician prediction of survival (CPS) and the association between CPS and the prognostic confidence of clinicians in ambulatory medical oncology outpatients. Methods: Eight medical oncologists estimated the expected survival of their patients in a prospective cohort study. They were asked to provide a temporal type of CPS in weeks, together with their level of confidence for each prediction (0–100%). We analyzed the accuracy of CPS, the association between CPS and the prognostic confidence, and the characteristics of patients showing inaccurate CPS. Results: A total of 200 advanced cancer patients were enrolled and the median overall survival was 7.6 months. CPS was accurate in 67 (33.5%) patients, underestimated in 87 (43.5%), and overestimated in 46 (23.0%). The overall accuracy of CPS for 12-week, 24-week, 36-week, and 48-week survival was 83.0%, 72.0%, 75.5%, and 74.0%, respectively. The specificity was highest for 12-week survival (90.2%) and the sensitivity was highest for 48-week survival (96.1%). The sensitivity of 12-week CPS was 51.4% and the area under the receiver operating characteristic (AUROC) curve was 0.79 (95% confidence interval [CI] 0.71–0.87). The prognostic confidence of clinicians was not significantly associated with the accuracy of prediction (P = 0.359). Patients with overestimated survival had significantly poorer global health status and physical/role/emotional functioning in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Additionally, they showed significantly higher levels of fatigue, nausea/vomiting, pain, dyspnea, and loss of appetite. Conclusion: The overall accuracy of CPS in predicting 12-week to 48-week survival was high in medical oncology outpatients. However the sensitivity of 12-week CPS was low and prognostic confidence was not associated with the accuracy of CPS. Patients with overestimated CPS showed poorer quality of life and higher symptom burden.


  • Open Access

    Notification of Terminal Status and Advance Care Planning in Patients with Cancer

    by Si Won Lee, M.D.

    Si Won Lee, M.D.. J Hosp Palliat Care 2022;25:42-9. https://doi.org/10.14475/jhpc.2022.25.1.42